Call Us: 1.800.873.5297

Jun
30

By

Xarelto® Blood Thinning Medication Causes Uncontrolled Bleeding, New Lawsuit Alleges

According to a recent lawsuit filed in the Philadelphia County Court of Common Pleas (Stuntebeck v. Johnson & Johnson, et al.), the anticoagulant drug, Xarelto® (rivaroxaban), is alleged to cause serious and uncontrolled internal bleeding that might be irreversible, that could result in life-threatening injuries and even death. The anti-clotting medication Xarelto®, which is marketed […]

Jun
25

By

Drug Compounder Working Under Unsanitary Conditions, FDA Reports

After a March review, the FDA stated that the Alabama-based Medaus Pharmacy has sterility issues in its facility prompting concerns regarding the safety of its products. The FDA issued a warning letter on January 15, 2014, notifying the drug compounder that state health regulators and inspectors found the pharmacy was selling drugs without prescriptions. Such […]

Jun
24

By

Researchers Aim to Test Experimental Drugs to Alter Circadian Rhythms

Two neurology professors aim to begin testing drugs that could positively alter the body’s circadian rhythms (i.e., the body’s internal clock that control it’s biological workings from sleeping and eating to cardiovascular function). Studies have shown that disrupting the body’s internal clock, for example by working night shift, can increase an individual’s risk for developing […]

Jun
23

By

New Studies Reveal Effects of Testosterone Therapy

Two recent studies have shed some light on the effects that testosterone replacement therapies have on men. In particular, the studies revealed that exercise and obesity significantly impact the success rate of testosterone replacement therapy. Dr. Min Gu Park from Inje University in South Korea conducted a study, which demonstrated that exercise may influence the […]

Jun
18

By

FDA Approves New Drug Developed to Treat MRSA Infections

The U.S. Food and Drug Administration (FDA) has approved the intravenous drug Dalvance to treat bacterial skin infections, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Dalvance is the first drug labeled as a Qualified Infectious Disease Product (QIDP) to receive FDA approval. MRSA is a life-threatening bacteria that has become resistant to antibiotics and is often […]

Jun
17

By

GlaxoSmithKline (GSK) Settles Promotion Claims: $105 Million Settlement

Bloomberg News reports that GlaxoSmithKline (GSK), the U.K.’s largest drug manufacturer, settled claims nationwide alleging the drug manufacturer illegally promoted asthma and antidepressant drugs. The company will contribute $105 million to a settlement fund over claims asserted by California, New York, and more than 40 other states. California will receive the bulk of the settlement […]

Jun
16

By

Doctors Criticize Low Testosterone Drug Manufacturers’ Marketing Ploy During Men’s Health Week

Two Dartmouth doctors are criticizing low testosterone therapy manufacturers for their marketing tactics of the Low-T therapy during Men’s Health Week. The event is sponsored by AbbVie and Pfizer, two key manufacturers of testosterone replacement products. While Men’s Health Week is a campaign designed to “heighten the awareness of preventable health problems” among men and boys, […]

Jun
12

By

FDA Alert: Class II Recall Issued on Hypertension Pill Found in Allergy Drug Bottles

The Indian drug-manufacturer, Zydus Cadila, has recalled 10,200 bottles of its allergy-relief medication from the United States after it found one of its 25 mg bottles contaminated with 25 mg of atenolol, a medication used to treat hypertension (high blood pressure) and angina (chest pain).  The FDA classified the recall as a Class II, which […]

Jun
11

By

Kristine Kraft of Schlichter, Bogard & Denton, LLP Reports on the Formation of a New MDL for Claims Alleging Injuries from Testosterone Replacement Therapy Drugs

On June 6, 2014, the Judicial Panel on Multidistrict Litigation (JPML) entered an order (Case MDL No. 2545, Doc No. 211) consolidating all claims filed in federal court alleging injuries involving testosterone products before The Honorable Judge Matthew F. Kennerly in the United States District Court for the Northern District of Illinois in an MDL […]

Jun
10

By

FDA Approves First-Ever Nasal Testosterone Treatment, Natesto™

Trimel Pharmaceuticals Corporation recently announced that the U.S. Food and Drug Administration (FDA) approved the first and only low testosterone nasal gel, Natesto™. The self-administered product has been approved for adult males as a replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone. Tom Rossi, Trimel Pharmaceuticals Corporation President and CEO, […]

« Older Posts

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.

Copyright © 2013 Schlichter Bogard & Denton